ZURICH (Reuters) - Swiss contract drug maker Lonza (LONN.S) has “strong support” from U.S. President Donald Trump to get equipment for its project to make Moderna’s (MRNA.O) COVID-19 vaccine candidate and does not expect delays, its chairman said on Friday.
“We are doing very well having access to the people, we can build up the teams in Portsmouth and in Visp to manufacture in the future these drug substances,” Chairman Albert Baehny told reporters after reporting first-half results. “There are basically no major issues in equipment, it’s a bit more complicated than the people, but I don’t think we’ll be facing delays because of delays in equipment delivery, as we see it today. We have strong support from the Trump Administration to have access to the equipment, as well.”
Reporting by John Miller; Editing by Michael Shields